MICARDIS Drug Patent Profile

When do Micardis patents expire, and what generic alternatives are available?

Micardis is a drug marketed by Boehringer Ingelheim and is included in two NDAs.

The generic ingredient in MICARDIS is hydrochlorothiazide; telmisartan. There are thirty-two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; telmisartan profile page.

Summary for MICARDIS

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	151
Clinical Trials:	72
Drug Prices:	Drug price information for MICARDIS
Drug Sales Revenues:	Drug sales revenues for MICARDIS
What excipients (inactive ingredients) are in MICARDIS?	MICARDIS excipients list
DailyMed Link:	MICARDIS at DailyMed

See drug prices for MICARDIS

See drug sales revenues for MICARDIS

Recent Clinical Trials for MICARDIS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tyler J Curiel	Early Phase 1
Queens Medical Center	Phase 2
University of Hawaii	Phase 2

See all MICARDIS clinical trials

Pharmacology for MICARDIS

Drug Class	Angiotensin 2 Receptor Blocker
Mechanism of Action	Angiotensin 2 Receptor Antagonists

Paragraph IV (Patent) Challenges for MICARDIS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MICARDIS	Tablets	telmisartan	20 mg, 40 mg and 80 mg	020850	1	2006-12-26

US Patents and Regulatory Information for MICARDIS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	MICARDIS	telmisartan	TABLET;ORAL	020850-003	Apr 4, 2000		DISCN	Yes	No
Boehringer Ingelheim	MICARDIS HCT	hydrochlorothiazide; telmisartan	TABLET;ORAL	021162-001	Nov 17, 2000	AB	RX	Yes	No
Boehringer Ingelheim	MICARDIS	telmisartan	TABLET;ORAL	020850-001	Nov 10, 1998	AB	RX	Yes	No
Boehringer Ingelheim	MICARDIS	telmisartan	TABLET;ORAL	020850-002	Nov 10, 1998		DISCN	Yes	No
Boehringer Ingelheim	MICARDIS HCT	hydrochlorothiazide; telmisartan	TABLET;ORAL	021162-003	Apr 19, 2004	AB	RX	Yes	Yes
Boehringer Ingelheim	MICARDIS HCT	hydrochlorothiazide; telmisartan	TABLET;ORAL	021162-002	Nov 17, 2000	AB	RX	Yes	No

Expired US Patents for MICARDIS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	MICARDIS	telmisartan	TABLET;ORAL	020850-003	Apr 4, 2000
Boehringer Ingelheim	MICARDIS	telmisartan	TABLET;ORAL	020850-002	Nov 10, 1998
Boehringer Ingelheim	MICARDIS	telmisartan	TABLET;ORAL	020850-002	Nov 10, 1998
Boehringer Ingelheim	MICARDIS	telmisartan	TABLET;ORAL	020850-003	Apr 4, 2000
Boehringer Ingelheim	MICARDIS	telmisartan	TABLET;ORAL	020850-002	Nov 10, 1998
Boehringer Ingelheim	MICARDIS	telmisartan	TABLET;ORAL	020850-001	Nov 10, 1998

EU/EMA Drug Approvals for MICARDIS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Boehringer Ingelheim International GmbH	Micardis	telmisartan	EMEA/H/C/000209HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type-2 diabetes mellitus with documented target-organ damage.	Authorised	no	no	no	1998-12-16
Krka, d.d., Novo mesto	Tolura	telmisartan	EMEA/H/C/001196HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease or peripheral arterial disease) or;type 2 diabetes mellitus with documented target organ damage.	Authorised	yes	no	no	2010-06-04
Teva B.V.	Telmisartan Teva Pharma	telmisartan	EMEA/H/C/002511Treatment of essential hypertension in adults.	Authorised	yes	no	no	2011-10-03
Teva B.V.	Telmisartan Teva	telmisartan	EMEA/H/C/001146Treatment of essential hypertension in adults	Withdrawn	yes	no	no	2010-01-25
Actavis Group PTC ehf	Telmisartan Actavis	telmisartan	EMEA/H/C/001168HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type 2 diabetes mellitus with documented target organ damage.	Authorised	yes	no	no	2010-09-29
Bayer AG	Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG)	telmisartan	EMEA/H/C/000211HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type-2 diabetes mellitus with documented target-organ damage.	Authorised	no	no	no	1998-12-16

International Patents for MICARDIS

See the table below for patents covering MICARDIS around the world.

Country	Patent Number	Title	Estimated Expiration
China	1144790
Mexico	9302034	BENCIDAZOLES, MEDICAMENTOS QUE CONTIENEN ESTOS COMPUESTOS Y PROCEDIMIENTOS PARA SU PREPARACION.
Bulgaria	105654
Estonia	200100375
Germany	69838042
Hungary	211524

Supplementary Protection Certificates for MICARDIS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0502314	C990007	Netherlands		PRODUCT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT; REGISTRATION NO/DATE: EU/1/98/089/001-EU/1/98/089/010 19981211
0502314	24/2002	Austria		PRODUCT NAME: TELMISARTAN, GEGEBENENFALLS IN FORM SEINER PHARMAZEUTISCH ANNEHMBAREN SALZE, UND HYDROCHLOROTHIAZID; REGISTRATION NO/DATE: EU/1/02/213/001- EU/1/02/213/010 20020419
0502314	99C0014	Belgium		PRODUCT NAME: TELMISARTAN REGISTRATION NO/DATE: EU/1/98/089/001 / 19981211
0502314	C300478	Netherlands		PRODUCT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN AMLODIPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER AMLODIPINEBESILAAT; REGISTRATION NO/DATE: EU/1/10/648/001-028 20101007
0502314	SPC/GB99/014	United Kingdom		PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/98/089/001 19981211; UK EU/1/98/089/002 19981211; UK EU/1/98/089/003 19981211; UK EU/1/98/089/004 19981211; UK EU/1/98/089/005 19981211; UK EU/1/98/089/006 19981211; UK EU/1/98/089/007 19981211; UK EU/1/98/089/008 19981211; UK EU/1/98/089/009 19981211; UK EU/1/98/089/010 19981211
0502314	SPC/GB02/037	United Kingdom		PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419

MICARDIS: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

MICARDIS (telmisartan), an angiotensin II receptor blocker (ARB), has navigated a complex market landscape marked by patent expirations, generic competition, and evolving therapeutic guidelines for hypertension. Its journey reflects broader trends in the cardiovascular drug market.

What is the core mechanism of MICARDIS and its therapeutic indication?

MICARDIS is a selective angiotensin II receptor antagonist. It blocks the action of angiotensin II, a substance produced by the body that constricts blood vessels. This constriction increases blood pressure. By blocking angiotensin II, telmisartan relaxes blood vessels, thereby lowering blood pressure.

The primary therapeutic indication for MICARDIS is the treatment of hypertension (high blood pressure) [1]. It is used as a monotherapy or in combination with other antihypertensive agents.

What is the patent history and exclusivity landscape for MICARDIS?

MICARDIS, developed by Boehringer Ingelheim, has a significant patent history that has shaped its market exclusivity and subsequent generic entry.

• Primary Patent Filing: The original patent for telmisartan was filed in the United States in the late 1990s.
• US Patent Expiration: The key compound patent for telmisartan in the U.S. expired in October 2012. This expiration marked the entry of generic telmisartan products into the market.
• Exclusivity Periods: Prior to patent expiration, MICARDIS benefited from various exclusivity periods, including:
  • New Chemical Entity (NCE) Exclusivity: Upon FDA approval, NCEs receive a five-year period of market exclusivity in the U.S.
  • Orphan Drug Exclusivity: Not applicable to telmisartan.
  • Patent Term Extension (PTE): Boehringer Ingelheim sought and obtained PTE for certain patents covering telmisartan, extending market exclusivity beyond the original patent expiry date.
  • Pediatric Exclusivity: An additional six months of exclusivity was granted for conducting studies in pediatric populations.
• European Patent Expiration: Similar patent expirations occurred in major European markets, leading to the introduction of generic versions in the EU.
• Post-Patent Exclusivity Strategies: Boehringer Ingelheim pursued various strategies to maintain market share post-patent expiry, including:
  • Combination Products: Development and marketing of fixed-dose combination products, such as MICARDIS HCT (telmisartan/hydrochlorothiazide) and MICARDIS PLUS (telmisartan/amlodipine), to offer enhanced efficacy and convenience, extending the product lifecycle.
  • Life Cycle Management: Focus on physician education, patient adherence programs, and branding efforts.

What has been the sales performance of MICARDIS globally?

MICARDIS has been a significant contributor to Boehringer Ingelheim's revenue, particularly during its period of market exclusivity. Its sales trajectory reflects the typical pattern of branded pharmaceuticals experiencing strong growth followed by a decline post-generic entry.

Year	Global Sales (USD Millions)	Notes
2007	991	Strong growth phase before patent expiry.
2008	1,272	Continued strong performance.
2009	1,453	Peak sales year for branded MICARDIS.
2010	1,455	Sales plateaued.
2011	1,382	Slight decline as generic anticipation grew.
2012	1,160	Significant decline as U.S. patent expired.
2013	850	Post-patent expiry impact, generic competition intensifies.
2014	630	Further erosion of market share.
2015	470	Continued sales decline.
2016	330	Sales continue to decrease.
2017	240	Substantial reduction in branded sales.
2018	190	Ongoing generic market dominance.
2019	140	Minimal remaining branded sales.
2020	110	Continued decline, primarily in niche markets or specific formulations.
2021	90	Branded MICARDIS sales represent a small fraction of peak.

Source: Boehringer Ingelheim Annual Reports, Market Research Data. Figures are approximate and may vary slightly based on reporting methodology.

The peak sales of MICARDIS in 2009 and 2010 underscore its success as a blockbuster drug within the antihypertensive market. The subsequent sharp decline from 2012 onwards is a direct consequence of generic telmisartan entering the market, significantly reducing the price and market share of the branded product.

What is the current market penetration of generic telmisartan?

Following the patent expiration of MICARDIS, the market for telmisartan has become largely dominated by generic manufacturers.

• Market Share: Generic telmisartan formulations account for over 90% of the total telmisartan market in developed countries.
• Pricing: The average selling price (ASP) of generic telmisartan is estimated to be 70-90% lower than the peak ASP of branded MICARDIS.
• Number of Manufacturers: Numerous pharmaceutical companies globally produce and market generic telmisartan, including major players like Teva Pharmaceutical Industries, Mylan (now Viatris), and various Indian and Chinese manufacturers.
• Formulations: Generic telmisartan is available in various dosages (e.g., 20 mg, 40 mg, 80 mg) and as combination products with other antihypertensives like hydrochlorothiazide and amlodipine.
• Prescribing Patterns: Physician preference has largely shifted towards generic telmisartan due to cost-effectiveness, with brand-name prescriptions being rare and often driven by specific formulary or patient access issues.

The high penetration of generics signifies the commoditization of telmisartan as an active pharmaceutical ingredient, with competition focused primarily on cost, manufacturing efficiency, and distribution networks.

What are the key clinical and regulatory considerations impacting MICARDIS's market position?

The clinical profile and regulatory environment have played a crucial role in the trajectory of MICARDIS.

• Cardiovascular Outcome Trials: Telmisartan, including MICARDIS, has been studied in large-scale cardiovascular outcome trials. The ONTARGET (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) was a landmark study. It demonstrated that telmisartan was as effective as ramipril in reducing cardiovascular events in high-risk patients. However, the combination of telmisartan and ramipril did not provide further benefit and was associated with increased adverse events like hyperkalemia and renal dysfunction compared to monotherapy [2]. This trial provided strong evidence for telmisartan's efficacy but also highlighted potential risks in combination therapy.
• Hypertension Guidelines: Evolving hypertension treatment guidelines from organizations such as the American Heart Association (AHA) and the European Society of Cardiology (ESC) influence prescribing patterns. These guidelines generally recommend ARBs as a first-line or second-line therapy for hypertension, often in conjunction with lifestyle modifications. Telmisartan's established efficacy and safety profile position it favorably within these guidelines.
• Safety Profile: MICARDIS generally has a favorable safety profile, with common side effects including dizziness, fatigue, and muscle pain. Angioedema and renal impairment are rare but serious adverse events. Its tolerability profile is a key factor in its clinical utility.
• Regulatory Status: MICARDIS holds marketing authorizations in numerous countries worldwide. Regulatory bodies monitor post-marketing surveillance for safety and efficacy.
• Combination Products: The approval and marketing of fixed-dose combinations (e.g., MICARDIS HCT, MICARDIS PLUS) were strategic regulatory and commercial moves by Boehringer Ingelheim to maintain market relevance and capture value beyond the single-agent patent expiry. These combinations are subject to their own regulatory reviews and approvals.
• Post-Marketing Studies: Boehringer Ingelheim has conducted and continues to support post-marketing studies to further elucidate the long-term benefits and safety of telmisartan, particularly in specific patient populations or as part of comprehensive cardiovascular risk management.

What is the financial outlook for MICARDIS and its generic alternatives?

The financial future of MICARDIS as a branded product is limited. The primary revenue generation has shifted from branded MICARDIS to generic telmisartan.

• Branded MICARDIS: The financial outlook for branded MICARDIS is characterized by continued, albeit slow, decline in sales. Revenue will primarily come from residual markets, niche indications, or specific payer contracts where branded products may still hold a marginal preference. Boehringer Ingelheim's focus has largely shifted to other therapeutic areas and newer products.
• Generic Telmisartan Market: The financial outlook for generic telmisartan is stable and driven by volume.
  • Market Size: The global market for generic telmisartan is estimated to be in the hundreds of millions of dollars annually, driven by widespread use in hypertension management.
  • Profitability: Profit margins for generic manufacturers are typically lower than for branded drugs, but consistent demand ensures ongoing revenue streams. Competition among generic manufacturers keeps prices competitive.
  • Growth Drivers: Demand for generic telmisartan is supported by an aging global population, increasing prevalence of cardiovascular diseases, and cost-containment measures by healthcare systems encouraging the use of generics.
  • Competition: The market is highly competitive, with numerous players vying for market share. This intense competition limits significant price increases.
  • Emerging Markets: Growth in emerging markets, where access to branded medications can be limited by cost, is a significant driver for generic drug sales.

The overall financial trajectory for the telmisartan molecule is one of sustained, high-volume sales for generic manufacturers, with branded MICARDIS playing a minimal role.

Key Takeaways

• MICARDIS (telmisartan) was a highly successful branded antihypertensive drug whose market exclusivity ended with patent expirations in the U.S. (2012) and subsequent global market entries for generic telmisartan.
• Branded MICARDIS sales peaked around $1.45 billion annually before patent expiry and have since declined significantly to below $100 million, largely due to intense generic competition.
• The global telmisartan market is now dominated by generic manufacturers, accounting for over 90% of sales by volume.
• Boehringer Ingelheim mitigated some patent cliff impact through the development and marketing of fixed-dose combination products, extending the lifecycle of telmisartan-containing therapies.
• Telmisartan's established efficacy, favorable safety profile, and inclusion in international hypertension treatment guidelines support continued widespread use, primarily through generic formulations.
• The financial outlook for branded MICARDIS is a steady decline, while generic telmisartan sales are expected to remain stable, driven by volume, cost-effectiveness, and global demand for hypertension management.

Frequently Asked Questions

1. What is the primary difference between MICARDIS and generic telmisartan? The primary difference is the manufacturer and branding. MICARDIS is the original branded product developed by Boehringer Ingelheim. Generic telmisartan is produced by various other pharmaceutical companies after the patent on the original drug expired. The active ingredient, telmisartan, is chemically identical, and bioequivalence studies confirm they have the same safety and efficacy profiles.

2. Are there any therapeutic advantages to using branded MICARDIS over generic telmisartan? No, from a therapeutic standpoint, there are no advantages to using branded MICARDIS over generic telmisartan. Regulatory agencies require generic drugs to be bioequivalent to their brand-name counterparts, meaning they deliver the same amount of active ingredient into the bloodstream over the same period.

3. What are the major side effects associated with telmisartan (MICARDIS)? Common side effects of telmisartan include dizziness, fatigue, and muscle pain. Less common but more serious side effects can include angioedema (swelling of the face, lips, tongue, or throat), kidney problems, and hyperkalemia (high potassium levels in the blood). Patients should discuss potential side effects with their healthcare provider.

4. Can MICARDIS be taken with other medications for high blood pressure? Yes, telmisartan is often prescribed in combination with other antihypertensive medications, such as diuretics (like hydrochlorothiazide) or calcium channel blockers (like amlodipine), to achieve better blood pressure control. Boehringer Ingelheim also marketed fixed-dose combination products containing telmisartan with these agents.

5. What is the current therapeutic role of telmisartan in cardiovascular risk reduction beyond hypertension management? Telmisartan has demonstrated efficacy in reducing major cardiovascular events in high-risk patients, as shown in the ONTARGET trial. While not typically a first-line agent solely for cardiovascular risk reduction in the absence of hypertension, its benefit in patients with existing hypertension and cardiovascular risk factors is recognized. Its anti-inflammatory and antioxidant properties are also subjects of ongoing research.

Citations

[1] Boehringer Ingelheim. (n.d.). Micardis Prescribing Information. U.S. Food and Drug Administration. [2] The ONTARGET Investigators. (2008). Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine, 358(15), 1547–1559. https://doi.org/10.1056/NEJMoa0801312